Compare CODA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | ENTX |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.7M | 147.4M |
| IPO Year | 2007 | 2015 |
| Metric | CODA | ENTX |
|---|---|---|
| Price | $10.87 | $2.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 112.8K | ★ 406.8K |
| Earning Date | 06-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 0.36 | 0.22 |
| Revenue | ★ $20,316,161.00 | $42,000.00 |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $29.94 | ★ $12.48 |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $7.80 | $0.91 |
| 52 Week High | $18.00 | $4.20 |
| Indicator | CODA | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 41.86 |
| Support Level | $10.85 | $2.71 |
| Resistance Level | $12.24 | $2.78 |
| Average True Range (ATR) | 0.43 | 0.18 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 78.44 | 17.17 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.